UK-based clinical stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ: TCBP) announced on Wednesday that European Patent Office (EPO) has granted a patent covering the use of modified gamma delta cells for the treatment of cancer and viral indications.

The firm aims to proceed with the patent process in specific European countries aligning with its commercial strategy.

Bryan Kobel, TCBP CEO, said, 'We are pleased to further expand our patent portfolio at TCBP with this European patent for Modified Gamma Delta t-cells. TCBP continues to focus on our immediate applications for TCB008 while developing future high value gamma delta assets for other indications such as solid tumours. We believe gamma deltas can be a high impact therapeutic when modified with the potential to outpace current CAR and modified t-cells in safety and efficacy, patent protecting these approaches gives us a competitive moat and further value in a potential acquisition scenario.'